A UK drug trial aimed at helping people with diabetes recover from coronavirus has received financial backing from a major healthcare provider in the United Arab Emirates.
Abu Dhabi-based Mubadala Healthcare pledged on Sunday to part-fund the trial, which is known as Arcadia.
The Arcadia trial is testing an immune-dampening drug that may be able to help diabetics, a high-risk group from COVID-19, overcome the effects of the virus. It began in September and samples the drug on patients with mild or moderate coronavirus symptoms.
For more on coronavirus, visit our dedicated section.
“The trial will determine whether this oral drug improves clinical outcomes via increased glucose control and a potential effect on the immune system,” wrote Diabetes.org.uk.
“[The] Research grant will enhance efforts to achieve better healthcare outcomes for more than one million diabetic patients in the UAE,” tweeted Mubadala.
.@Mubadala Healthcare is part-funding the trial of an immune-dampening drug in the UK that will help patients with diabetes overcome the effects of COVID-19. The move helps to strengthen #AbuDhabi and the UAE’s leading role in the global fight against COVID-19. pic.twitter.com/KD0emZW2cU
— مكتب أبوظبي الإعلامي (@admediaoffice) November 8, 2020
The healthcare provider, whose network includes Cleveland Clinic Abu Dhabi and Abu Dhabi Telemedicine Center, did not specify how much money it would be contributing to the trials.
Globally, people with diabetes have suffered from higher death rates from the coronavirus pandemic.
The World Health Organization lists people with diabetes as among the group most at risk of severe illness or death from COVID-19.
Read more:
Mubadala plans healthcare fund for 2021 following coronavirus demand spike
Coronavirus: Abu Dhabi new entry requirement includes up to 3 mandatory PCR tests
UAE’s Mubadala to increase investment in life sciences, medical technology
